Vectus Biosystems Limited (ASX:VBS)

Market Cap	6.53M +63.2%
Revenue (ttm)	2.77M +478.7%
Net Income	1.56M
EPS	0.03
Shares Out	62.18M
PE Ratio	3.74
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7
Open	0.1050
Previous Close	0.1050
Day's Range	0.1050 - 0.1050
52-Week Range	0.0740 - 0.4550
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Vectus Biosystems

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address diseases driven by pathological tissue scarring. Its lead compound is VB0004, currently under phase Ib clinical human trial, which targets the prevention and reversal of fibrosis in the lungs, heart, and kidneys. The company was incorporated in 2005 and is based in Rosebery, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: VBS

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error